Inflammasomes are macromolecular complexes formed in response to pathogen‐associated molecular patterns (PAMPs) and danger‐associated molecular patterns (DAMPs) that drive maturation of the pro‐inflammatory cytokines interleukin (IL)‐1β and IL‐18, and cleave gasdermin D (GSDMD) for induction of pyroptosis. Inflammasomes are highly important in protecting the host from various microbial pathogens and sterile insults. Inflammasome pathways are strictly regulated at both transcriptional and post‐translational checkpoints. When these checkpoints are not properly imposed, undue inflammasome activation may promote inflammatory, metabolic and oncogenic processes that give rise to autoinflammatory, autoimmune, metabolic and malignant diseases. In addition to clinically approved IL‐1‐targeted biologics, upstream targeting of inflammasome pathways recently gained interest as a novel pharmacological strategy for selectively modulating inflammasome activation in pathological conditions.

中文翻译：

---

炎症小体途径的治疗调节。

炎症小体是响应病原体相关分子模式 (PAMP) 和危险相关分子模式 (DAMP) 而形成的大分子复合物，它们驱动促炎细胞因子白细胞介素 (IL)-1β 和 IL-18 的成熟，并裂解gasdermin D。 GSDMD) 用于诱导细胞焦亡。炎症小体在保护宿主免受各种微生物病原体和无菌侵害方面非常重要。炎症小体通路在转录和翻译后检查点都受到严格调控。当这些检查点没有被正确施加时，过度的炎症小体激活可能会促进炎症、代谢和致癌过程，从而导致自身炎症、自身免疫、代谢和恶性疾病。除了临床批准的 IL-1 靶向生物制剂，